Company Name
Shanghai BioEngine Sci-Tech Co., Ltd.
Year of Establishment
2014
Annual Turnover(USD)
More than 99,999,999
Company Introduction
BioEngine Sci-Tech Co., Ltd. was founded in 2014, by Professor Wen-Song Tan and his team at the State Key Laboratory of Bioreactor Engineering of East China University of Science and Technology. We specialize in providing high-quality & cost effective serum-free media and related technical services for biopharmaceutical companies in the antibody, vaccine, and cell & gene therapy fields.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
https://www.bioengine-global.com/
Milestone
Particular Year
1986
Technical team for large-scale culture of animal cells established to enter antibody and vaccine industry
1995
Opened up the research direction of stem cell and tissue engineering
2014
Shanghai BioEngine Sci-Tech Co., Ltd was established
2015
Presided Over Zhangjiang Major Development Project of Gov. Sp. Fund
Xeno series serum-free medium for MDCK cells launched
2016
Round A Financing (Shanghai STVC Group)
Zhangjiang Pilot Production and R&D Center launched
2017
The First culture media company passed by ISO13485 QS Certificated (BSI Audit)
Low serum culture medium for BHK cells launched
2018
Eden series of CD medium for CHO cells for antibody production launched
HIPP series of serum-free medium for immune effector cells for cell therapy launched
Vigor series of serum-free medium for insect cells launched
Bofit series of serum-free medium for MDBK cells launched
Tac series of serum-free medium for BHK cells launched
Proli series of serum-free medium for PK15 cells launched
Celer series of serum-free medium for 293 cells launched
2019
Honored as "SHANGHAI TECHNICAL INNOVATION ENTERPRISE"
Round B financing (China SME Development Fund Co., Ltd.)
Eden series of perfusion medium for CHO cells launched
Pesche series of serum-free medium for Vero cells launched
2020
Won the Title of Shanghai "NEW SPECIALIZED" Small and Medium-sized Enterprise
Human rabies vaccine production project using Pesche series of serum-free medium for Vero cells successfully entered clinical phase III.
Personalized precision therapy program using HIPP-T009 serum-free medium for immune effector cells enterd clinical trials for the first time in China
2021
Round B+ Financing completed. (Shanghai Hankang Equity Investment Management Co., Ltd)
Phase II manufacturing site (Shanghai Beijin Biotech Co., Ltd.) launched.
2022
Round B++ financing completed(Legend Capital lead invest)